Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
| العنوان: | Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C? |
|---|---|
| المؤلفون: | Manh Thông Dao, Nicolas Picard, Patrick Saulnier, Véronique Loustaud-Ratti, Dominique Larrey, Pascal Veillon, Françoise Lunel-Fabiani, Alexandra Ducancelle, Louis d’Alteroche, Nathalie Boyer-Darrigand, Hélène Le Guillou-Guillemette, Isabelle Fouchard-Hubert |
| المساهمون: | Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire HIFIH, Université d'Angers ( UA ), Micro et nanomédecines biomimétiques ( MINT ), Université d'Angers ( UA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Bretagne Loire ( UBL ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Univ Angers, Okina |
| المصدر: | Journal of Interferon and Cytokine Research Journal of Interferon and Cytokine Research, Mary Ann Liebert, 2016, 36 (3), pp.204-14. 〈http://online.liebertpub.com/doi/10.1089/jir.2015.0131〉. 〈10.1089/jir.2015.0131〉 Journal of Interferon and Cytokine Research, Mary Ann Liebert, 2016, 36 (3), pp.204-214. ⟨10.1089/jir.2015.0131⟩ Journal of Interferon and Cytokine Research, 2016, 36 (3), pp.204-214. ⟨10.1089/jir.2015.0131⟩ |
| بيانات النشر: | HAL CCSD, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Simple noninvasive index, Sustained virology response, Gene Expression, Hepacivirus, Pharmacology, medicine.disease_cause, Gastroenterology, Polyethylene Glycols, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pegylated interferon, Significant fibrosis, Pyrophosphatases, Epoetin beta, HCV-Infected Patients, virus diseases, Alanine Transaminase, Anemia, Middle Aged, Viral Load, Recombinant Proteins, 3. Good health, Treatment Outcome, Interferon alpha, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, RNA, Viral, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, ITPA, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, Growth factors, Viral load, medicine.drug, Adult, medicine.medical_specialty, Genotype, Hepatitis C virus, Immunology, Alpha interferon, Antiviral Agents, Polymorphism, Single Nucleotide, 03 medical and health sciences, Virology, Internal medicine, Ribavirin, medicine, Humans, Double blind, Aspartate Aminotransferases, Combination therapy, Erythropoietin, [ SDV ] Life Sciences [q-bio], business.industry, Interleukins, Virus genotype-1 patients, Interferon-alpha, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Cell Biology, Hepatitis C, Chronic, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, digestive system diseases, 030104 developmental biology, chemistry, Antiviral treatment, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Interferons, business |
| الوصف: | International audience; To investigate the impact of epoetin beta (EPO) on sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with peginterferon-ribavirin (RBV). Controlled, randomized, pragmatic multicenter study to assess 2 strategies, ie, the use (EPO group) or nonuse (control group) of EPO in terms of achieving SVR in treatment-naive, genotype non-2/non-3 HCV-infected patients receiving a 48-week treatment regimen of pegylated interferon alpha-2a (peg-IFN) plus RBV (randomization 2:1). The single-nucleotide polymorphisms of interferon lambda 3 (IFNL3) (rs12979860 and rs8099917), interferon lambda 4 (IFNL4) (ss469415590), and inosine triphosphatase (ITPA) (rs1127354 and rs7270101) were determined retrospectively. Two hundred twenty-seven patients were included in the study. In the global population (n = 227), the overall SVR rate was 52% (118/227). Nonresponse and relapse occurred in respectively 46/227 (20.3%) and 42/227 (18.5%) patients. In the intention-to-treat analysis, 55.5% of patients with anemia (n = 164) had a SVR, specifically 57.4% in the EPO group versus 52.4% in the control group, but the difference was not statistically significant. In the anemic population, independent factors associated with SVR were IFNL3 and IFNL4 polymorphisms, pretreatment HCV RNA level, iron level, and aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio. EPO has little impact on SVR in patients treated with peg-IFN+RBV and should be recommended only for patients with severe anemia. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1079-9907 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a899fcef8f6398c395b5a6288361aecd https://hal.archives-ouvertes.fr/hal-01392291 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a899fcef8f6398c395b5a6288361aecd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10799907 |
|---|